Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

11/12/24 9:55:17 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CYTK alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 CYTOKINETICS INC COMMON STOCK Cusip #23282W605 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #23282W605 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 12,216,482 Item 6: 0 Item 7: 12,415,642 Item 8: 0 Item 9: 12,415,642 Item 11: 10.518% Item 12: HC Cusip #23282W605 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 12,415,642 Item 8: 0 Item 9: 12,415,642 Item 11: 10.518% Item 12: IN Item 1(a). Name of Issuer: CYTOKINETICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 350 OYSTER POINT BOULEVARD South San Francisco, CA 94080 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 23282W605 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 12,415,642 (b) Percent of Class: 10.518% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 12,415,642 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CYTOKINETICS INC. No one other person's interest in the COMMON STOCK of CYTOKINETICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of CYTOKINETICS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $CYTK alert in real time by email

Recent Analyst Ratings for

$CYTK

Date	Price Target	Rating	Analyst
1/28/2026	$87.00	Overweight	Barclays
12/18/2025	$95.00	Neutral → Buy	Goldman
7/30/2025		Mkt Perform	Raymond James
4/24/2025	$55.00	Overweight	Barclays
2/7/2025	$86.00	Buy	Citigroup
1/22/2025	$80.00	Buy	Stifel
11/8/2024	$80.00	Outperform	RBC Capital Mkts
8/13/2024	$85.00 → $60.00	Buy → Neutral	Goldman

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

11/12/24 9:55:17 AM ET

$CYTK

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CYTK alert in real time by email

Recent Analyst Ratings for

$CYTK

Date	Price Target	Rating	Analyst
1/28/2026	$87.00	Overweight	Barclays
12/18/2025	$95.00	Neutral → Buy	Goldman
7/30/2025		Mkt Perform	Raymond James
4/24/2025	$55.00	Overweight	Barclays
2/7/2025	$86.00	Buy	Citigroup
1/22/2025	$80.00	Buy	Stifel
11/8/2024	$80.00	Outperform	RBC Capital Mkts
8/13/2024	$85.00 → $60.00	Buy → Neutral	Goldman

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CYTK

Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CYTK

$CYTK
Analyst Ratings

Barclays resumed coverage on Cytokinetics with a new price target

Cytokinetics upgraded by Goldman with a new price target

Raymond James resumed coverage on Cytokinetics

$CYTK
Press Releases

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$CYTK
SEC Filings

Cytokinetics Incorporated filed SEC Form 8-K: Other Events

Cytokinetics Incorporated filed SEC Form 8-K: Other Events

Cytokinetics Incorporated filed SEC Form 8-K: Leadership Update

$CYTK
Insider Trading

Director Daly James M was granted 197 shares (SEC Form 4)

Director Wysenski Nancy was granted 98 shares, increasing direct ownership by 0.32% to 30,971 units (SEC Form 4)

Director Wierenga Wendell was granted 98 shares, increasing direct ownership by 0.30% to 32,542 units (SEC Form 4)

$CYTK
Leadership Updates

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

Cytokinetics Names Jim Daly to Board of Directors

Cytokinetics Names Robert E. Landry to Board of Directors

$CYTK
Financials

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

Cytokinetics to Announce Third Quarter Results on November 5, 2025

$CYTK
Large Ownership Changes

SEC Form SC 13G filed by Cytokinetics Incorporated